Zobrazeno 1 - 10
of 254
pro vyhledávání: '"T. K. Lau"'
Autor:
Carlos K. H. Wong, Kristy T. K. Lau, Ivan C. H. Au, Sophelia H. S. Chan, Eric H. Y. Lau, Benjamin J. Cowling, Gabriel M. Leung
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-7 (2024)
Abstract Currently there is a lack of randomized trial data examining the use of the antiviral nirmatrelvir/ritonavir in paediatric patients with SARS-CoV-2 infection. This target trial emulation study aims to address this gap by evaluating the use o
Externí odkaz:
https://doaj.org/article/231ad1a19f524d35b5f0b8d19196631d
Autor:
Carlos K. H. Wong, Jonathan J. Lau, Ivan C. H. Au, Kristy T. K. Lau, Ivan F. N. Hung, Malik Peiris, Gabriel M. Leung, Joseph T. Wu
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-13 (2023)
Abstract Reports of symptomatic rebound and/or test re-positivity among COVID-19 patients following the standard five-day treatment course of nirmatrelvir/ritonavir have sparked debates regarding optimal treatment timing and dosage. It is unclear whe
Externí odkaz:
https://doaj.org/article/ef711f78c8cc4c7594791ac27a81a695
Publikováno v:
mSystems, Vol 9, Iss 3 (2024)
ABSTRACTWastewater treatment plants (WWTPs) are indispensable biotechnology facilities for modern cities and play an essential role in modern urban infrastructure by employing microorganisms to remove pollutants in wastewater, thus protecting public
Externí odkaz:
https://doaj.org/article/ac9548ffd9fe46f5828d574fb8395fda
Autor:
Carlos K. H. Wong, Kristy T. K. Lau, Ivan C. H. Au, Xi Xiong, Matthew S. H. Chung, Belle Y. C. Leung, Eric H. Y. Lau, Benjamin J. Cowling
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Objectives: This retrospective cohort study aims to explore head-to-head clinical outcomes and complications associated with tocilizumab or baricitinib initiation among hospitalized COVID-19 patients receiving dexamethasone.Methods: Among 10,445 COVI
Externí odkaz:
https://doaj.org/article/b5d7d80de6a041128603037e464ebe99
Autor:
Carlos K H Wong, Kristy T K Lau, Ivan C H Au, Eric H Y Lau, Leo L M Poon, Ivan F N Hung, Benjamin J Cowling, Gabriel M Leung
Publikováno v:
The Lancet Infectious Diseases. 23:683-695
Autor:
Carlos K H, Wong, Ivan C H, Au, Kristy T K, Lau, Eric H Y, Lau, Benjamin J, Cowling, Gabriel M, Leung
Publikováno v:
The Lancet Infectious Diseases. 22:1681-1693
Data on the effectiveness of oral antivirals in patients with mild-to-moderate COVID-19 are urgently needed. This retrospective cohort study aimed to evaluate the clinical and virological outcomes associated with molnupiravir or nirmatrelvir-ritonavi
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Real-world effectiveness of nirmatrelvir–ritonavir against BA.4 and BA.5 omicron SARS-CoV-2 variants
Publikováno v:
The Lancet Infectious Diseases. 23:639-640
Autor:
Eric H. Y. Lau, Carlos K. H. Wong, Xi Xiong, Matthew S.H. Chung, Benjamin J. Cowling, Ivan C H Au, Kristy T K Lau
Publikováno v:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Background Evidence is lacking about any additional benefits of introducing remdesivir on top of dexamethasone, and the optimal timing of initiation. Methods In a territory-wide cohort of 10 445 coronavirus disease 2019 (COVID-19) patients from Hong
Autor:
David T. W. Lui, Matthew S. H. Chung, Eric H. Y. Lau, Kristy T. K. Lau, Ivan C. H. Au, Chi Ho Lee, Yu Cho Woo, Carlos K. H. Wong, Benjamin J. Cowling
Publikováno v:
JAMA Network Open. 6:e2314393
ImportanceDiabetes and COVID-19 are both global pandemics, and type 2 diabetes is a common comorbidity in patients with acute COVID-19 and is proven to be a key determinant of COVID-19 prognosis. Molnupiravir and nirmatrelvir-ritonavir are oral antiv